Misoprostol
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-MISOPROSTOL |
|---|---|
| Type | Drug |
| Aliases | CytotecМізопростол |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Synthetic prostaglandin E1 analog |
|---|---|
| Mechanism | Synthetic prostaglandin E1 analog with gastric mucosal protective effects (mucus + bicarbonate secretion, decreased gastric acid via enterochromaffin-like cell inhibition) and uterotonic activity. In oncology / cancer-prevention context: investigated as endometrial protection in tamoxifen users (theoretical rationale — endometrial PGE pathways). Evidence base is limited and inconsistent; not guideline-recommended for routine tamoxifen-associated endometrial protection. Primary FDA indications are NSAID-induced peptic ulcer prophylaxis and (off-label) obstetric uses. |
| Typical dosing | NSAID ulcer prevention: 200 mcg PO QID with food and at bedtime (alternative: 200 mcg BID-TID for tolerability). Tamoxifen endometrial protection (off-label, research context only): 200 mcg PO regimens have been studied — NOT a guideline-supported use; clinician judgment + IRB if pursued. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Warnings
- Misoprostol can cause uterine rupture, abortion, premature birth, or birth defects — use in pregnancy can lead to pregnancy loss; women must have negative pregnancy test before initiation and use effective contraception
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. PRIMARY indication is NSAID-induced peptic ulcer prevention. CONTROVERSIAL alternative-only use for tamoxifen-associated endometrial protection — NOT NCCN/ESMO recommended; small studies have not shown clear benefit. Engine should NOT auto- recommend; reserved as clinician-judgment alternative pending dedicated guideline. Strict pregnancy exclusion mandatory. Source cited (SRC-NCCN-BCELL-2025) is closest in-KB until dedicated peptic-ulcer- prevention or tamoxifen-endometrium sources land.
Used By
No reverse references found in the YAML corpus.